On March 11 2021, the European Medical Agency highlighted two relevant issues, after the decision by the Danish Health Authority to temporarily suspend its vaccination campaign with Vaxzevria (the COVID-19 vaccine by AstraZeneca) following the reports of thromboembolic events (TE) associated with the administration of the vaccine: 1) lack of evidence of a cause/effect relationship between the vaccine and TE; 2) the number of reported TE (30 in around 5,000,000 vaccinated people) was no higher than that expected [1].
